Summary of preclinical, translational, and clinical evidence of the DRibbles vaccine
| In the Lab | Bench to Bedside | In the Clinic |
|---|---|---|
| • DRibbles vaccine comprises autophagosome-packaged cellular proteins, short-lived proteins and ribosomal proteins that may be missed by endogenous immunity | • The DPV-001 DRibbles contains over 2,000 proteins, of which 25 are known tumor-associated antigens | • Dribbles vaccine + docetaxel was well tolerated in a phase I NSCLC trial |
| • DRibbles delays growth in both “autologous” and “allogeneic” pre-preclinical models | • The DPV-001 cell lines contain thousands of mutations and polymorphisms that could function as altered-peptide ligands | • A Phase II trial comparing DRibbles + either GM-CSF or Imiquimod in stage IIIA/B NSCLC is ongoing |
| • DRibbles contains innate immunity mediators (DAMPs) and surface ligands for CLEC9a, which facilitate uptake by APCs for cross-presentation | • Each lung adenocarcinoma sequence from the TCGA database shares at least one mutation with the polymorphisms found in DPV-001 | • A Phase I trial of DRibbles + imiquimod + low-dose cyclophosphamide is ongoing |
| • DPV-001 contains common oncogene mutants such as KRAS G12C | • DRibbles induced increased antibody reactivity in the first 2 patients treated on a phase II trial |